Pharm Chapter 12 Bbc: Hiv And Aids

Front 1

Nucleoside reverse transcriptase inhibitors MOA

Back 1

The triphosphate analogs interfere with and inhibit reverse transcriptase, making it impossible for the virus to make DNA from its RNA

Front 2

Name the NRTI's

Back 2

Didanosine, Lamivudine, Tenofovir, Zidovudine, Emtricitabine

Front 3

MOA of non-nucleoside reverse transcriptase inhibitors

Back 3

Direct inhibition of reverse trancriptase

Front 4

Name the drugs in the NNRTI's

Back 4

Efavirenz and Nevirapine

Front 5

MOA of Protease inhibitors

Back 5

Inhibition of protease; prevents the viral protein products from being cleaved to form functional structures

Front 6

You see a drug that ends in -navir -- what class of drug does this belong?

Back 6

Protease inhibitors

Front 7

Name the protease inhibitors?

Back 7

Ritonavir, Atazanavir, Darunavir, Indinavir, and Nelfinavir

Front 8

Name the fusion inhibitor?

Back 8

Enfuvirtide

Front 9

MOA of Enfuvirtide

Back 9

Prevents fusion of the HIV virus particle with the outer membrane of the host target cell, preventing infection of the cell by the virus. Binds to the gp41 on the virus preventing the fusion event.

Front 10

MOA of Integrase inhibitors

Back 10

Inhibition of HIV-1 integrase preventing integration and insertion of HIV DNA into human DNA

Front 11

Name the Integrase Inhibitor

Back 11

Raltegravir

Front 12

MOA of CCR5 antagonists

Back 12

work to block the CCR5 co receptor located on white blood cells targeted by HIV thereby preventing viral entry into the cell.

Front 13

Adverse effects of CCR5 antagonists?

Back 13

Hepatotoxic, increase the risk for infections and malignancies, systemic allergic reactions and cause cardiovascular events such as MI

Front 14

Name the CCR5 antagonist?

Back 14

Maraviroc

Front 15

What is the goal in HIV treatment?

Back 15

Inhibit viral replication, thereby permitting re-establishment of an effective immune system. Also, inhibition of viral rplication will also reduce viral load, decreasing the number of viral particles exposed to the drug and therefoe decrease development of drug resistant mutants

Front 16

When should HIV therapy be started?

Back 16

Anyone who is HIV (+) with AIDS defining illness (opportunistic infections, HIV complicating infections or AIDS associated cancer)
HIV positive patient with a CD4 count <350 cells/microliter
HIV positive patient with HIV associated nephropathy
HIV positive patient with current HBV infection
HIV positive patient who is pregnant

Front 17

What combinations are used in HIV therapy?

Back 17

2 NRTIs + (1 NNRTI OR 1 boosted protease inhibitor OR 1 integrase inhibitor OR CCR5 antagonist)

Front 18

Name the specific regimen and drugs recommended for pregnant HIV positive patient

Back 18

2 NRTI's + 1 PI
Lopinavir, Zidovudine, and Lamivudine

Front 19

HIV prophylaxis?

Back 19

Daily pharmacologic regimen of Tenofovir and Emtribtabine